Values as of: 2024-09-19
COMMON STOCK | Medical Instruments & Supplies |
Last Closing
USD 49.5Change
+0.17 (+0.34)%Market Cap
USD 2.41BVolume
0.71MAnalyst Target
N/AVerdict
Verdict
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts. Address: 200 Summit Drive, Burlington, MA, United States, 01803
Company Website : https://www.azenta.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ISRG | Intuitive Surgical Inc |
+7.92 (+1.64%) |
USD 174.07B |
| COO | The Cooper Companies, Inc. Com.. |
+0.57 (+0.52%) |
USD 22.15B |
| ALGN | Align Technology Inc |
+4.16 (+1.64%) |
USD 19.21B |
| HOLX | Hologic Inc |
+0.68 (+0.83%) |
USD 18.85B |
| RGEN | Repligen Corporation |
+3.75 (+2.64%) |
USD 7.84B |
| MMSI | Merit Medical Systems Inc |
+1.52 (+1.54%) |
USD 5.60B |
| XRAY | Dentsply Sirona Inc |
+0.19 (+0.71%) |
USD 5.33B |
| ICUI | ICU Medical Inc |
+5.05 (+2.87%) |
USD 4.37B |
| LMAT | LeMaitre Vascular Inc |
+1.33 (+1.50%) |
USD 2.02B |
| STAA | STAAR Surgical Company |
+0.21 (+0.67%) |
USD 1.59B |
N/A
| Market Performance vs. Industry/Classification (Medical Instruments & Supplies) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -24.01% | 36% | F | 28% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -24.01% | 33% | F | 28% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 1.73% | 56% | F | 45% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 1.73% | 53% | F | 43% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -4.02% | 45% | F | 34% | F | ||
| Dividend Return | -4.02% | 43% | F | 31% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 24.45% | 86% | B+ | 70% | C- | ||
| Risk Adjusted Return | -16.45% | 45% | F | 30% | F | ||
| Market Capitalization | 2.41B | 79% | B- | 81% | B- | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector
